UNIV OF IOWA CALGB INSTITUTIONAL GRANT

爱荷华大学 CALGB 机构补助金

• 批准号: 2556356
• 负责人: GERALD H CLAMON
• 金额: $ 8.53万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-04-01 至 2001-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2556356
• 关键词: AIDS related neoplasm /cancer; aging; antineoplastics; bone marrow transplantation; breast neoplasms; cancer prevention; cancer registry /resource; carmustine; chemoprevention; cis platinum compound; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; finasteride; fluorouracil; gastrointestinal neoplasms; health care cost /financing; hormone therapy; human genetic material tag; human subject; human therapy evaluation; interleukin 2; leucovorin; leukemia; lymphoma; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; oncology nursing; paclitaxel; pathology; prostate neoplasms; psychology; quality of life; respiratory neoplasm; tamoxifen; tissue resource /registry; weight loss

DESCRIPTION (adapted from the applicant's abstract): This application is to continue the University of Iowa participation in studies of Cancer and Leukemia Group B. Our goals over the next 5 year period will include: (1) maintenance of accrual to clinical trials of over 100 patients per year (2) add new studies to the CALGB program in the area of: (a) use of Perillyl alcohol as an inhibitor of RAS function both as an antineoplastic in combination with other agents and possibly as a chemopreventive agent, (b) assessment of RAS mutations in the peripheral blood of women who have had chemotherapy as an adjuvant for breast cancer and would be at risk for myelodysplastic syndrome and leukemia, (c) further trials of omega three fatty acids as therapy for cancer cachexia and as an adjuvant to therapy in cancer, (d) continue to develop combined modality therapy for stage 3 and 4 non-small cell lung cancer. In particularly, a pilot at the University of Iowa of Gemcitabine/Carboplatin for non-small cell lung cancer may be able to help CALGB in the future (3) expand CALGB trials to rural hospitals in Iowa where University of Iowa physicians are now providing oncology care (Washington, Iowa; Keosauqua, Iowa; Dubuque, Iowa; Muscatine, Iowa; Fairfield, Iowa; Fort Madison, Iowa)

描述（改编自申请人的摘要）：本申请旨在 继续爱荷华州大学参与癌症研究， 白血病B组。我们在未来五年的目标包括：（1） 维持每年超过100例患者的临床试验累积（2） 在CALGB方案中增加以下领域的新研究：（a）紫苏的使用 酒精作为RAS抑制剂， 与其它药剂组合并可能作为化学预防剂，（B） 评估有以下病史的女性外周血中的RAS突变： 化疗作为乳腺癌的辅助治疗， 骨髓增生异常综合征和白血病，（c）欧米伽三的进一步试验 脂肪酸作为癌症恶病质的治疗和作为癌症恶病质治疗的辅助剂 （d）继续为3期和4期癌症开发综合疗法 非小细胞肺癌。 特别是，一个试点在大学的 爱荷华州的吉西他滨/卡铂治疗非小细胞肺癌可能能够 （3）将CALGB试验扩大到农村医院， 爱荷华州，爱荷华州大学的医生现在提供肿瘤治疗 （华盛顿，爱荷华州;基奥索夸，爱荷华州;迪比克，爱荷华州;马斯卡廷，爱荷华州; 费尔菲尔德，爱荷华州;麦迪逊堡，爱荷华州）